Table 1 The demographic and oncological characteristics
Patient characteristics | Arm A (cisplatin 100 mg/m2) | Arm B (cisplatin 40 mg/m2) | p |
|---|---|---|---|
N = 26 | N = 24 | ||
Gender | |||
Male | 25 (96.2%) | 23 (95.8%) | 1.000 |
Female | 1 (3.8%) | 1 (4.2%) | |
Age (years old) | |||
Mean (range) | 49.2 (33–63) | 49.0 (32–65) | 0.941 |
pT | |||
pT1/2 | 14 (53.8%) | 11 (45.8%) | 0.778 |
pT3/4 | 12 (46.2%) | 13 (54.2%) | |
pN | |||
pN0 | 0 (0%) | 2 (8.3%) | |
pN1 | 5 (19.2%) | 8 (33.3%) | |
pN2 | 21 (80.8%) | 14 (58.3%) | |
Stage | |||
Stage II | 0 (0%) | 1 (4.2%) | |
Stage III | 3 (11.5%) | 4 (16.7%) | |
Stage IV | 23 (88.5%) | 19 (79.2%) | |
Differentiation | |||
Well | 7 (26.9%) | 5 (20.8%) | |
Moderate | 15 (57.7%) | 17 (70.8%) | |
Poor | 4 (15.4%) | 2 (8.3%) | |
Primary Site | |||
Buccal | 10 (38.5%) | 9 (37.5%) | |
Tongue | 10 (38.5%) | 11 (45.8%) | |
Gum | 5 (19.2%) | 3 (12.5%) | |
Others | 1 (3.8%) | 1 (4.2%) | |
ECS | |||
No | 5 (19.2%) | 9 (37.5%) | 0.211 |
Yes | 21 (80.8%) | 15 (62.5%) | |
Margin | |||
Negative | 25 (96.2%) | 20 (83.3%) | 0.182 |
Positive | 1 (3.8%) | 4 (16.7%) | |
Tumor size (mm) | |||
Mean (range) | 31.19 (12–68) | 34.13 (12–60) | 0.414 |